Sector: MedicalEURX (NASDAQ: EURX)
Headlines
- Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
Nov 05, 2009 07:02 AM | EURX, RX
- Eurand to Participate in Upcoming Investor Conferences
Oct 28, 2009 12:29 PM | BCS, EURX
- Eurand Completes Public Offering, Including Exercise of the Underwriters' Over-Allotment Option, for Total Net Proceeds of Approximately $103.9 Million
Oct 28, 2009 08:30 AM | EURX
- Eurand Announces Proposed Public Offering of Ordinary Shares
Oct 15, 2009 06:00 AM | DB, EURX
- Eurand Announces Conference Call on Third Quarter 2009 Financial Results
Oct 05, 2009 09:01 AM | EURX
- Eurand Announces Filing of F-3 Registration Statement
Sep 28, 2009 05:42 PM | EURX
- Eurand to Present at UBS Global Life Sciences Conference
Sep 16, 2009 08:47 AM | EURX, UBS
- Eurand Granted FDA Approval for ZENPEP(TM)
Aug 28, 2009 06:35 AM | EURX
- Eurand Successfully Completes Registration Procedure for Paracetamol
ODT 250 and 500 mg in the European Union
Jul 20, 2009 07:02 AM | EURX
- FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
Jun 22, 2009 08:19 PM | AMGN, BMY, EURX, FOLD, MEDX, ONTY
- Eurand Announces Pricing of Offering of Ordinary Shares
Oct 22, 2009 09:53 AM | EURX
- Ingenico Announces the Acquisition of Easycash, a Leading Payment Services Provider Based in Germany
Sep 25, 2009 03:53 AM | EURX, NSR, NUAN, WNS
- Eurand to Participate in Upcoming Investor Conferences
Aug 19, 2009 08:01 AM | EURX
- Eurand Reports Recent Developments and Second Quarter 2009 Financial Results
Aug 06, 2009 07:00 AM | EURX
- Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250 and 500 mg in the European Union
Jul 20, 2009 07:00 AM | EURX
- Eurand Announces Conference Call on Second Quarter 2009 Financial Results
Jul 08, 2009 09:01 AM | EURX
- FDA Extends Review Period for Eurand's ZENPEP(TM) Pancreatic Enzyme Replacement Therapy
Jun 22, 2009 07:00 AM | EURX
- Eurand to Present at UBS Global Specialty Pharmaceuticals Conference in London
May 20, 2009 11:21 AM | EURX
- FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
May 11, 2009 07:02 AM | EURX, GSK
- Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
May 11, 2009 07:00 AM | EURX, GSK
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
EURX
|
Compare to S&P
|
| YTD |
52.66 %
|
33.07 %
|
| 4 Weeks |
-11.90 %
|
-12.83 %
|
| 12 Weeks |
-6.90 %
|
-9.21 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 33.33 %
|
|
EPS Growth in Last Year: 86.67 %
|
|
Sales Growth in Last Quarter: 10.77 %
|
|
Sales Growth in Last Quarter: -24.61 %
|
|
